## Vincenzo Serretta

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7816295/vincenzo-serretta-publications-by-year.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26 40 712 12 h-index g-index citations papers 853 2.98 41 2.9 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
40	Sexual dysfunction in dialytic patients. A prospective cross-sectional observational study in two hemodialysis centers. <i>Archivio Italiano Di Urologia Andrologia</i> , <b>2021</b> , 93, 215-220	1.6	O
39	A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder cancer not undergoing maintenance after 6-week intravesical prophylaxis. <i>Urologia</i> , <b>2021</b> , 3915603211022285	1.2	O
38	Virtual Clinical and Precision Medicine Tumor Boards-Cloud-Based Platform-Mediated Implementation of Multidisciplinary Reviews Among Oncology Centers in the COVID-19 Era: Protocol for an Observational Study. <i>JMIR Research Protocols</i> , <b>2021</b> , 10, e26220	2	1
37	Time to safely omit bladder cuff removal for low-risk upper tract urothelial carcinoma. <i>Minerva Urology and Nephrology</i> , <b>2021</b> , 73, 417-420	2.3	
36	Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , <b>2021</b> , 13, 1756287221995683	3.2	O
35	Is Kelami's Method Still Useful in the Smartphone Era? The Virtual 3-Dimensional Reconstruction of Penile Curvature in Patients With Peyronie's Disease: A Pilot Study. <i>Journal of Sexual Medicine</i> , <b>2021</b> , 18, 209-214	1.1	4
34	Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study. <i>Urologia Internationalis</i> , <b>2020</b> , 104, 396-401	1.9	3
33	Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single-centre open-label uncontrolled trial. <i>Andrologia</i> , <b>2020</b> , 52, e13705	2.4	2
32	Can We Clinically Distinguish Anejaculation From Retrograde Ejaculation in Patients on AA-Blockers Therapy for Lower Urinary Tract Symptoms?. <i>Urology</i> , <b>2020</b> , 139, 129-133	1.6	1
31	Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis. <i>Radiologia Medica</i> , <b>2020</b> , 125, 220-227	6.5	6
30	Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m: A multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 601.e11-601.e16	2.8	1
29	Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study. <i>BJU International</i> , <b>2019</b> , 124, 116-123	5.6	3
28	Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e751-e758	3.3	10
27	Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer. <i>Investigative and Clinical Urology</i> , <b>2019</b> , 60, 91-98	1.9	9
26	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. <i>World Journal of Urology</i> , <b>2019</b> , 37, 507-514	4	57
25	Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 964-9	6 <del>3</del> .8	0
24	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. <i>European Urology Oncology</i> , <b>2018</b> , 1, 403-410	6.7	41

## (2005-2018)

23	Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5053-5060	3.6	12
22	Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT). <i>Pathology Research and Practice</i> , <b>2017</b> , 213, 165-169	3.4	3
21	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 484.e19-484.e25	2.8	39
20	The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer. <i>Urologia</i> , <b>2016</b> , 83, 145-148	1.2	3
19	Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?. <i>Urologia Internationalis</i> , <b>2016</b> , 96, 20-4	1.9	18
18	Mitomycin C from birth to adulthood. <i>Urologia</i> , <b>2016</b> , 83, 2-6	1.2	3
17	Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked!. <i>Infectious Diseases</i> , <b>2015</b> , 47, 732-3	3.1	1
16	Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Gufin: results of a retrospective multicenter study of 2451 patients. <i>European Urology</i> , <b>2015</b> , 67, 74-82	10.2	149
15	Clinical pitfalls in diagnosis of nonmuscle-invasive bladder cancer. <i>Urologia</i> , <b>2015</b> , 82 Suppl 2, S1-4	1.2	2
14	Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy. <i>Urology Annals</i> , <b>2015</b> , 7, 21-5	1	1
13	Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. <i>Urology</i> , <b>2014</b> , 84, 1141-6	1.6	27
12	Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. <i>Urology</i> , <b>2013</b> , 81, 277-81	1.6	14
11	A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. <i>Clinical Genitourinary Cancer</i> , <b>2012</b> , 10, 174-9	3.3	14
10	A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. <i>BJU International</i> , <b>2010</b> , 106, 212-7	5.6	21
9	Cigarette smoking and drinking water source: correlation with clinical features and pathology of superficial bladder carcinoma. <i>Urologia Internationalis</i> , <b>2009</b> , 82, 318-23	1.9	5
8	Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. <i>Urologia Internationalis</i> , <b>2009</b> , 83, 452-7	1.9	5
7	Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment. <i>Journal of Urology</i> , <b>2008</b> , 180, 886-90; discussion 891	2.5	7
6	Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. <i>Urology</i> , <b>2005</b> , 65, 65-9	1.6	36

5	TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. <i>European Urology</i> , <b>2004</b> , 45, 730-5; discussion 735-6	10.2	28
4	Management of symptomatic benign prostatic hyperplasia in southern Italy: a retrospective analysis of the Sicilian-Calabrian Society of Urology (SSCU) of 32,000 patients. <i>Urologia Internationalis</i> , <b>2003</b> , 71, 16-21	1.9	3
3	Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2003</b> , 129, 472-6	4.9	8
2	Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. <i>Urology</i> , <b>2002</b> , 60, 623-7	1.6	174
1	Virtual Clinical and Precision Medicine Tumor Boards©loud-Based PlatformMediated Implementation of Multidisciplinary Reviews Among Oncology Centers in the COVID-19 Era: Protocol for an Observational Study (Preprint)		1